|Page (1) of 1 - 07/12/18||email article||print page|
(July 12, 2018)
ST. LOUIS, July 12, 2018 /PRNewswire-PRWeb/ -- PLUTON BIOSCIENCES FILES FOR PATENT ON FIRST DISCOVERY
Each year, mosquitoes kill approximately 725,000 people by spreading blood-borne disease and viruses.
And one species, the Aedes aegypti mosquito, has been notably destructive. Aedes is a vector for dengue and yellow fever, Chikungunya, and the Zika virus, which emerged in 2015 causing birth defects in children of mothers who carry the virus.
For many companies, a cure would involve treating the disease only after a person has been infected.
But for Pluton Biosciences, a St. Louis-based biotech start-up, a cure means stopping the diseases before they start.
Using its industry disrupting Micromining™ process, in just three months time Pluton Biosciences was able to identify two novel bacterial solutions to kill the Aedes larvae, opening a new path to explore in mosquito vector control. Pluton filed to patent these new biopesticides in April 2018.
How is finding a solution in three months possible?
Pluton uses its proprietary Micromining™ platform to "mine" billions of microbes from a collection of diverse soil samples. By fusing classic microbiology assay design to automation, image capture techniques, and computational biology, Micromining™ quickly and inexpensively isolates microbes with novel modes of action 100 times faster than current leading research labs.
But Pluton Biosciences is more than just a research company.
By partnering with manufacturers to create natural bioproducts for the pesticide, agriculture, pharmaceutical, and bioremediation industries, Pluton Biosciences aspires to solve global problems and helps ensure a sustainable future for our planet.
Pluton Biosciences, building a sustainable tomorrow by Micromining Nature's Solutions™ today.
SOURCE PRWeb House E-Commerce
Copyright 2014 PR Newswire. All Rights Reserved
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter